Advanced lung cancer
Conditions
Interventions
cystine and theanine
Sponsors
Inoue Akira
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) any gender over 20 years old 2) Diagnosed as lung cancer 3) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 - 2 4) With 5 percent weight loss within 6 months and appetite loss, and 2 factors among 3 factors below (i) fatigue (ii) systemic muscle weakness (iii) CRP>0.5 mg/dL or Hb 1500 / microlitre (ii) platelet count > 75000 / microlitre (iii) Hemoglobin > 8.0 g / dL (iv) Total bilirubin < 2.0 mg / dL (v) AST < 100 U / L (vi) ALT < 100 U / L (vii) Serum creatinine < 1.5 mg / dL 6) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Take in a healthy product of amino acids (including protein) or those derived from herb including Saint Jones Wirt except the multivitamin nutritional supplement 2) Planned the chemotherapy with the moderate emetic above-mentioned anticancer agent (ex. Platinum agents, irinotecan, amurubicin, celitinib, crizotinib) during the examination period (one months) 3) Treatment with Anamorelin is planned within the period of this study 4) Impossible oral intake 5) With malabsorption syndrome or active gastrointestinal bleeding or past history of the gastric resection 6) Being pregnant or nursing baby 7) With immunodeficiency or phenylketonuria 8) Withe cognitive impairment such as dementia or delirium 9) With neurologic mental obstacle to affect the data collection 10) Impossible communication because of aphasia, loss of voice, or dysarthria 11) Judged as inappropriate for registration by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of QOL (FAACT-SEA) from baseline to Day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL ( FAACT (A/CS) ) on Day 28, IL-6, Adverse Events | — |
Contacts
Public ContactAkira Inoue
Tohoku University Hospital
Outcome results
None listed